Abionic

18/12/2023

Healthcare providers, emergency care givers and all point of care facilities must make it a priority to detect sepsis early in order to save lives. There is a growing body of evidence that supports the use of biomarker detection, in particular, Pancreatic Stone Protein (PSP).

27/11/2023

The ACEM ASM 2023 last week demonstrated an array of technologies, techniques and concepts that enable professional teams to deliver exceptional patient care under pressure. The Abionic abioSCOPE 2.0 analyser is one such solution, changing the game when it comes to early sepsis detection.

Delegates visiting our stand were keen to find out about how the device provides a positive indication for sepsis up to 72 hours earlier than the current standard of care. Early diagnosis is key to good patient outcomes – every hour sepsis detection is delayed, survival rates decrease by 8%.

If you missed the team at the conference or want to know more about how you could revolutionise your point of care sepsis testing, visit https://au.getzhealthcare.com/products/medical-hospital/point-of-care-diagnostic-devices/abioScope%C2%AE-2.0/abioSCOPE-2.0.

10/11/2023

ACEM 38th Annual Scientific Meeting

21/09/2023

13/09/2023

Today, September 13, is World Sepsis Day.

Sepsis remains the second leading cause of death worldwide, claiming too many victims every year. At Abionic, we've harnessed the power of innovation to develop the world's fastest diagnostic platform, and our 5-minute sepsis test is leading the charge in this battle.

Our sepsis test has a predictive value of up to 3 days before the onset of symptoms, an invaluable advance in the fight against this devastating condition. This test is a game-changer for healthcare professionals, enabling them to identify patients at risk of developing sepsis long before symptoms appear. The test is an essential tool in intensive care units (ICUs) for pre-symptomatic identification, and in emergency departments (EDs) to confirm suspected cases of sepsis.

On this World Sepsis Day, we invite physicians and healthcare providers around the world to consider adopting our innovative diagnostic solutions. Together, we can redefine the way sepsis is detected and managed, and save countless lives in the process. Early detection is essential, and our technology is leading the way.

12/09/2023

Tomorrow, September 13th, marks World Sepsis Day, and we couldn't be prouder of our incredible team at Abionic for the invaluable contribution we're making in the battle against sepsis – the second leading cause of death worldwide.

At Abionic, we've developed groundbreaking medical technology that has the potential to save countless lives. Our 5-minute sepsis test, with a predictive value of up to 3 days before symptoms appear, is a game-changer in the healthcare industry. This test is not only revolutionizing the way we identify and manage sepsis, but it's also providing critical support to healthcare professionals in intensive care units (ICUs) and emergency departments (EDs) worldwide.

Sepsis is a silent killer that often goes undetected until it's too late. With our rapid diagnostic platform, we empower medical teams to identify sepsis in its earliest stages, enabling them to take proactive measures that can mean the difference between life and death. This technology is a testament to the dedication and innovation of our team, and it's an honor to be part of an organization that is making such a significant impact on global health.

As we observe World Sepsis Day, let's reflect on the progress we've made and the challenges that lie ahead. Together, we can continue to raise awareness, improve early detection, and ultimately reduce the devastating impact of sepsis on individuals and families around the world.

29/08/2023

🦠 Equip yourself now with the world's fastest COVID test to respond quickly to the rising tide of new COVID-19 cases! 🦠

In light of the recent increase in the number of COVID cases, it is imperative that we remain vigilant and proactive in our efforts to identify the SARS-CoV-2 virus in order to prevent its spread.

Our team has succeeded in developing the world's fastest saliva / nasopharyngeal COVID test, compatible with all variants. Our revolutionary nanotechnology has been listed on the European Common List and independently validated by several laboratories as one of the best performing solutions available on the market today.

As an example, one of our collaborators has been tested positive for COVID-19 a few days ago, and our test accurately detected the virus in around a minute, from a simple saliva sample.

Our sales department is now open to inquiries, and we invite anyone interested in our cutting-edge solution to contact us at sales@abionic.com.

Visit our website:
https://www.abionic.com/en/products

25/06/2023

Excellente émission “Mise au point” ce soir sur la télévision nationale suisse (RTS 1), dans laquelle j’ai pu m’exprimer sur les accords que nous devons rétablir avec nos voisins Européens. Les conséquences sont réelles pour les Medtechs et les milieux académiques, et nous ne sommes que les premiers.

Play RTS vous permet de visionner ou d'écouter de nombreuses émissions tv ou radio, quand et aussi souvent que vous le souhaitez.

13/06/2023

Exciting Announcement: Abionic has been honored with the prestigious 🌟 Swiss Medtech Award 2023! 🌟

At today's Swiss Medtech Day (the most important event in the Swiss medical technology industry, with over 700 participants gathered in Bern, Switzerland), Abionic won the Swiss Medtech Award!

Thanks to Bioalps for this nomination and to the jury who recognized that our ultra-fast point-of-care testing technology could revolutionize in vitro diagnostics, particularly in the field of sepsis diagnosis.

Winning the Swiss Medtech Award is an incredible honor and a fantastic opportunity for us to showcase our revolutionary technology, particularly our 5-minute sepsis test with a predictive value of 3 days before symptoms appear. This test not only enables the pre-symptomatic identification of patients at risk of developing sepsis but is also widely used to confirm sepsis in those presenting symptoms. Our technology has the potential to save countless lives, and this award validates the immense impact we will have worldwide.

We want to express our heartfelt congratulations to each and every one of our collaborators and partners for their exceptional contributions that have led to this extraordinary achievement. This recognition is a testament to your unwavering dedication, outstanding skills, and relentless pursuit of excellence. Together, we have accomplished something remarkable, and we couldn't be prouder of our team. Together, we are shaping the future of healthcare.

12/06/2023

For every hour that sepsis diagnosis and antibiotic therapy is delayed, patient survival rates decrease by 8%. Give your patients the best protection with the abioSCOPE from Abionic. This innovative solution detects the earliest markers of sepsis – Pancreatic Stone Protein (PSP) – up to 72 hours earlier than the current standard of care. The test is also fully compatible with hospital information systems for seamless workflow integration. Detect sepsis in patients up to 72 hours earlier with abioSCOPE.

Contact Getz Healthcare ANZ today or visit. https://www-au.getzhealthcare.com/products/medical-hospital/point-of-care-diagnostic-devices/abioScope%C2%AE-2.0

12/06/2023

The Pancreatic Stone Protein (PSP) point-of-care test on the Abionic abioSCOPE® enables the earliest detection of sepsis in just 5 minutes with one drop of blood. The PSP biomarker allows for the detection of sepsis up to 72hrs earlier than conventional sepsis markers. Our PSP test is fast, easy and reliable.

For details, contact info@cruinn.ie

04/03/2023

The innovative abioSCOPE® 2.0 analyser from Abionic makes the early detection and treatment of sepsis faster. This intuitive device utilises patented nanoflu...

14/02/2023

Get an insight of Aferetica workshop on the diagnosis of overwhelming inflammatory diseases, just as if you were there!

Through this constructive workshop Aferetica brought together leading experts to discuss challenges in the field. Sessions explored topics such as the use of biomarkers in the early detection and diagnosis of inflammatory diseases, the potential of PSP in sepsis diagnosis, and its application in COVID-19 detection.

Dr Pietro Caironi | Biomarkers: dream or reality?
Presentation: https://bit.ly/3RJ8jzL
Video: https://bit.ly/40HfSLm

Dr João Gonçalves Pereira | PSP and the diagnosis of sepsis
Presentation: https://bit.ly/3I97ywM
Video: https://bit.ly/3S18nLz

Dr Giuseppe Castellano | PSP and diagnosis in COVID-19
Presentation: https://bit.ly/3HN7vFt
Video: https://bit.ly/3HOqIqh

Read more: https://www.purificationtherapies.com/contributions-2022/

10/02/2023

Le tremblement de terre en Turquie et en Syrie a causé de la détresse et des dommages importants à de nombreuses personnes, dont à la famille de l'une de nos collaboratrices. Nous pouvons faire notre part en participant à une collecte de fonds pour les aider. Même une petite contribution peut faire une énorme différence dans la vie de quelqu'un dans le besoin.

Rejoignez-nous dans l'effort de soutenir les personnes touchées par ce drame.

Cliquez sur le lien pour faire un don et partagez ce post avec vos amis pour sensibiliser un plus grand nombre de personnes. Ensemble, nous pouvons faire la différence.

Merci pour votre soutien!

Hi, my name is Ayhan Sahin. I am native of Gaziantep. With my cou… Ayhan Sahin needs your support for My people in need hit by the earthquake in Turkey

20/01/2023

📈 « An increasing demand for single blood drop analysis”, according to the study report "The Global Single Blood Drop Analysis Market in 2023".

🥇 Abionic is grateful to be mentioned among the key players of the field.

This recognition highlights our commitment to providing reliable, timely results at the point-of-care from a single drop of blood. 🩸

💪 The Abionic’s team is more than determined to advancing POC diagnostics!

Read now https://bit.ly/3XMvgUi

Single Blood Drop Analysis Market size is rising upward in the past few years And it is estimated that the market will grow significantly in the forecasted period

19/01/2023

🎙 Hit play to hear Nicolas Durand, our CEO, talk about “Propelling diagnostics through miniaturization” in the latest episode of Impulse - Meeting Healthcare Pioneers.

In this podcast we learn about:
👉 How our core nanotechnology changes the traditional approach to diagnostics
👉 The efforts it takes to develop a new medical device and demonstrate its clinical efficacy
👉 The impact of Theranos scandal on medtech startups
And more …

A very exciting discussion with Mathieu Chaffard, listen now 🎧 https://bit.ly/3CVUQ1i

Nicolas Durand is the CEO of Abionic, a Swiss-based startup which developed and commercialises the abioSCOPE®, a unique diagnostic platform characterised by its compact size and ability to deliver high quality results in a fraction of time.  

18/11/2022

🔥Launching today! We’ve worked on the AMR campaign from
Learn more about the fight against AMR and the need for cross sector collaboration by going online or picking up a copy today’s Guardian https://bit.ly/3EdOsT8

23/09/2022

Abionic est très fière d'être labellisée comme l’un des 18 premiers Ambassadeurs de la Marque VAUD+ représentant l'excellence vaudoise. Nous allons continuer à agir comme acteur dans la santé contribuant à l’identité et la réputation d'excellence du canton de Vaud.

Abionic is very proud to be named as one of the first 18 Ambassadors of the VAUD+ Brand representing Vaud's excellence. We will continue to act as an actor in the health sector contributing to the identity and reputation of excellence of the State of Vaud.

+